MAGE-A4 TCR-transduced T cells

MAGE-A4 TCR-transduced T cells are genetically engineered autologous T cells expressing a high-affinity T cell receptor (TCR) specific for the melanoma-associated antigen A4 (MAGE-A4), a cancer/testis antigen highly expressed in a variety of solid tumors and restricted in normal tissues except testis and placenta. After isolation from the patient, T cells are modified (often by lentiviral transduction) to express this exogenous TCR, targeting intracellular MAGE-A4 peptides presented on tumor cells by MHC class I molecules, usually HLA-A*02. The engineered T cells are expanded and reinfused, where they can seek and destroy MAGE-A4 positive cancer cells, harnessing cytotoxicity and cytokine responses. Next-generation versions incorporate a CD8α co-receptor to boost CD4+ T cell cytotoxic and helper functions. The therapy is primarily being developed and commercialized as afamitresgene autoleucel (Tecelra) and uzatresgene autoleucel (ADP-A2M4CD8), including for FDA-approved use in synovial sarcoma and myxoid/round cell liposarcoma, with ongoing trials in other MAGE-A4+ tumors[1][2][3][6][7].

Brand names

Tecelra

Other names

MAGE-A4-targeted autologous TCR-T cellsMAGE-A-4-targeted autologous TCR-T cellsMAGE-A 4-targeted autologous TCR-T cellsMAGE-A4-specific TCR T cellsMAGE-A-4-specific TCR T cellsMAGE-A 4-specific TCR T cellsMAGE-A4 engineered T cellsMAGE-A-4 engineered T cellsMAGE-A 4 engineered T cells